Cambrex is the small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. Enjoy working with our experts to accelerate your small molecule therapeutics into the marketLearn more
EAST RUTHERFORD, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) — Cambrex Corporation (NYSE: CBM) (the “Company” or “Cambrex”) today announced the expiration, as of 12:01 a.m., Eastern Time, on September 22, 2019, of the 45-day “go shop” period under the previously announced Agreement and Plan of Merger, dated as of August 7, 2019 (the “Merger Agreement”), which provides for the Company to be acquired by an affiliate of the Permira funds in an all-cash transaction for $60.00 per share. […]Learn more
The Cambrex ripple represents the dynamic energy and passion of our people. It’s symbolic of the positive impacts that every employee has on our your business – every day – from personal connections through to teams, departments and sites.
Our people add value to your end goals, help grow your business and we’re consistently told you enjoy working with us.
Watch our video to learn how we can accelerate your small molecule therapeutics into the market.
Cambrex is a leading global supplier of more than 100 generic APIs.
With over 35 years’ experience and a growing team of over 2,000 experts servicing our global clients from our sites in North America and Europe, we are tried and trusted in branded and generic markets for API and dosage form development and manufacturing.
Cambrex can support your project in regulated, emerging and developing markets. We are in your neighborhood, wherever you are.